ABVC BioPharma, Inc. (ABVC) stock
ABVCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ECOC
$0.96−0.03 (-3.03%)
Close on Nov 12, 2026Market cap $25.59MP/E –Yield –
ABVC BioPharma profit margin
Profit margin (net margin) is net income as a percentage of revenue.
ABVC BioPharma's profit margin for the twelve months ending Dec 31, 2024 was -1656.4%. For fiscal 2025 it was -2671.8%, against -1656.4% the year before. The highest annual figure on record is -560.5% in fiscal 2019.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -2671.8% | −1015.4 |
| FY2024 | Dec 31, 2024 | -1656.4% | +3452.9 |
| FY2023 | Dec 31, 2023 | -5109.3% | −3415.8 |
| FY2022 | Dec 31, 2022 | -1693.5% | +1915.0 |
| FY2021 | Dec 31, 2021 | -3608.5% | −1415.4 |
| FY2020 | Dec 31, 2020 | -2193.1% | −1632.6 |
| FY2019 | Dec 31, 2019 | -560.5% | +2346.3 |
| FY2013 | Sep 30, 2013 | -2906.8% | +15811.8 |
| FY2012 | Sep 30, 2012 | -18718.6% | +19483.7 |
| FY2011 | Sep 30, 2011 | -38202.2% | −25409.1 |
| FY2010 | Sep 30, 2010 | -12793.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -256.6% | +234946.6 |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -37211.3% | −19505.6 |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -101.4% | +20784.5 |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -804.4% | +36247.6 |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -235203.2% | −233781.5 |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -17705.7% | −16879.9 |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -20885.9% | −12120.9 |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -37052.1% | −36457.9 |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -1421.7% | +21943.2 |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -825.8% | +998.9 |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -8765.0% | −2494.3 |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -594.2% | −140.0 |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -23364.9% | −15375.1 |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -1824.8% | +19.5 |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -6270.7% | −5306.5 |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -454.2% | +1207.6 |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -7989.9% | −6873.7 |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -1844.3% | −1171.8 |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -964.2% | −643.8 |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -1661.8% | −1250.3 |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -1116.2% | −874.1 |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -672.5% | −372.0 |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -320.4% | – |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -411.5% | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -242.1% | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -300.5% | – |
See a number that looks wrong?